Opinion of the Transparency Council – active substance octreotidum

At its meeting on 5 August 2024 2024, the Transparency Council adopted opinion No. 120/2024 on the on the inclusion in reimbursement of medicines containing the active substance octreotidum in the scope of indications for use or dosage or mode of administration different from those specified in the Summary of Product Characteristics, i.e. hyperinsulinism due to a cause other than specified in the SmPC and symptoms of hypersecretion occurring in the course of neuroendocrine tumors other than those specified in the SmPC

Publication on the list of opinions on active substances for off-label indications >>